Table 4.
Multiple-ordinal logistic regression models per clinical vignette
| Vignette 1a | Vignette 2b | |||||
|---|---|---|---|---|---|---|
| Variables tested | Odds ratio | 95% CI | p-value | Odds ratio | 95% CI | p-value |
| Belief of greater effectiveness of the new drug (vs. clinical equipoise) | 0.74 | 0.60–0.92 | 0.008 | – | – | – |
| Random allocation of study drugs (vs. medical decision) | 1.05 | .84–1.30 | 0.689 | – | – | – |
| Public research funding (vs. research financed by a drug company) | 1.29 | 1.04–1.60 | 0.022 | – | – | – |
| Rare disease (vs. frequent, heart diseases) | – | – | – | 0.90 | 0.71–1.14 | 0.387 |
| Genetic analysis of specimens (vs. blood protein analyses) | – | – | – | 1.19 | 0.94–1.50 | 0.147 |
| Automatic reporting of test results to the participant (vs. only upon request) | – | – | – | 1.12 | 0.89–1.42 | 0.334 |
| Excellent/very good health status (vs. good/fair/poor) | 0.78 | 0.60–1.02 | 0.065 | 1.42 | 1.07–1.89 | 0.016 |
| Opinion on research (from “very negative” to “very positive”) | 2.38 | 2.04–2.76 | < 0.001 | 2.71 | 2.31–3.18 | < 0.001 |
| Previous participation in clinical studies (vs. no participation) | 1.48 | 1.14–1.91 | 0.003 | 1.45 | 1.10–1.90 | 0.008 |
| Blood or organ donor (vs. not) | 1.51 | 1.21–1.88 | < 0.001 | 2.16 | 1.70–2.74 | < 0.001 |
Abbreviation: CI Confidence interval
a Among respondents, 1066 of 1118 (95.3%) had no missing data
b Among respondents, 1056 of 1109 (95.2%) had no missing data